

Lifen and iOMEDICO join forces to build a pan-European real-world oncology registry

Combining iOMEDICO's expertise in prospective clinical registries with Lifen's artificial intelligence infrastructure, the two partners offer pharmaceutical companies joint real-world data projects in oncology and haematology, with a single contact and a common methodology for each project and are laying the foundations for a new European approach to clinical research in oncology and hematology.

Paris and Freiburg, 10/08/2026 - Lifen, a French company specializing in health data with AI and iOMEDICO, a German provider of prospective real-world data in oncology and hematology, today announced a partnership to develop pan-European real-world data projects for pharmaceutical and biopharmaceutical companies. The announcement comes as new cancer medicines now are subject to a joint clinical assessment (JCA) at the European level, while national health technology assessment (HTA) bodies still ask for data that reflect local care. The partnership brings together Lifen's network of healthcare institutions and AI technology in France with iOMEDICO's prospective clinical registries and network of study sites in Germany. Projects will cover clinical practice, treatment pathways, biomarkers, real-world outcomes, and evidence to support HTA, with healthcare institutions involved in their design.

Addressing the fragmentation of European oncology data

Since January 2025, new oncology medicines seeking marketing authorization in the EU are subject to a Joint Clinical Assessment. Its scope consolidates the questions of all member states, which often means documenting several comparators and standards of care at once. Meanwhile, national HTA bodies continue to ask for data that reflects local care. To understand patient pathways and assess treatments in real-world settings, pharmaceutical companies need clinical data that are more comprehensive, longitudinal and representative of the diversity of Europe's healthcare systems. **These data, along with the expertise and hospital networks required to make use of them, remain scattered across countries and organizations. Lifen and iOMEDICO address these needs by combining French hospital data with German prospective registries – with a single contact and common methodology for each project.** Joint projects can characterize standard of care and treatment sequences, quantify patient subgroups, estimate biomarker prevalence, provide external control arms and generate post-launch evidence. The partnership brings together data, expertise and networks that are often fragmented across countries and organizations, making European projects simpler to set up and deliver. Participating hospitals and study sites, in turn, gain access to multicenter European research projects.

"Randomized controlled trials (RCTs) remain the gold standard, but there is a critical need to evaluate interventions in the real world to guide clinical decisions, inform future studies, and ultimately provide better patient care. At Lifen Research, our mission is to support the scientific and medical community by reinventing how research cohorts are built to address expanding clinical, scientific, and regulatory needs. We are thrilled to partner with iOMEDICO, as we share the same vision and commitment to the medical and scientific community. Together, we form one of the strongest networks in oncology clinical practice across France and Germany, and our goal is to build real-world research capacity throughout Europe." **says Jean-Frédéric Petit-Nivard, VP of Lifen Research.**

Prospective registries and routine care data

The two organizations operate at different stages of data generation.

Founded in 1996, iOMEDICO builds and runs prospective, quality-controlled clinical registries, that follow Good Registry Practice in line with the European Medicines Agency (EMA) requirements, covering more than 60,000 patients across the main cancer types. Since 2012, its registries have been referenced in around one in four German oncology benefit dossiers (AMNOG). Its network of more than 900 study sites in Germany includes university hospitals, general hospitals and specialist centers. Lif'en's research cohorts, on the other hand, are built from an AI that enables the extraction and structuration of clinical information directly from medical reports, at scale, building on Lif'en's 10-year experience partnering with nearly 1,000 hospitals in France. Lif'en's AI processes more than 60 million medical reports a year, and its hybrid approach - combining AI with expert review, was validated in a landmark study published in *Annals of Oncology* earlier in 2025. Together with Gustave Roussy, Lif'en's approach has already enabled the launch of national real-world cohorts in lung and prostate cancer. **Joint projects will therefore will enable the combination of longitudinal clinical depth, from German registries, with the breadth of routine care data from French hospitals, drawing on both partners' expertise in real-world research, treatment pathway analysis, and health economics and outcomes research (HEOR).**

Projects built on clinical expertise

The value of this collaboration rests on the data generated every day in healthcare institutions and on the work of the teams who document, verify and use them. iOMEDICO's registry data is documented prospectively at the treating sites and validated in real time; Lif'en's infrastructure is part of the daily workflow of French hospitals. Healthcare institutions and research teams remain involved in these projects. Their expertise is essential to define the relevant studied variables, ensure data quality, interpret results and produce analyses that are useful to patients and healthcare stakeholders. The partnership also gives medical institutions the opportunity to take part in multicenter, pan-European research projects.

"As an oncologist, I know that the most important questions about a new therapy are answered in everyday care, not only in clinical trials. For more than 25 years, we have documented that care prospectively, patient by patient. Together with Lif'en, we can now answer these questions across Europe – with data that HTA bodies accept." **Dr. Patrick Marschner, CMO of iOMEDICO**

In the coming months, Lif'en and iOMEDICO's teams will work on identifying the first joint projects and define a European roadmap in oncology and hematology. **In the long run, both partners intend to extend their offering to other European countries, building on the complementary strengths of their networks, registries and expertise.**

About Lif'en

Founded in 2015, Lif'en is a healthcare data company and a leader in digital health. With expertise in artificial intelligence, Lif'en provides a comprehensive suite of solutions that facilitate access to, structuring and secure sharing of healthcare data across care delivery and research. Today, nearly 1,000 hospitals and 20,000 community healthcare professionals use Lif'en's solutions to reduce administrative workload, personalize care and accelerate clinical research. Lif'en has 160 employees based throughout France. Learn more about Lif'en: www.lifen.fr

About iOMEDICO

Based in Freiburg, Germany, iOMEDICO is a research organization dedicated exclusively to oncology and hematology. For more than 25 years, iOMEDICO has designed and conducted clinical trials, registries and real-world data projects together with the pharmaceutical industry and a nationwide network of oncologists. Its prospective, longitudinal tumor registries cover more than 60,000 patients across all key tumor entities, including more than 26,000 patient-reported outcome data sets, and have resulted in more than 300 publications. Learn more about iOMEDICO: www.iomedico.com

Pharmaceutical companies interested in a joint project can reach out at: rwd@lifen.fr / rwd@iomedico.com